Navigation Links
Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results
Date:8/7/2009

$1,114,470 compared to $1,201,206 in the first six months of 2008, including non-cash stock-based compensation of $86,666 and $112,524, respectively.

As a development stage biopharmaceutical company, Catalyst has no revenues to-date. At June 30, 2009, the Company had cash and cash equivalents totaling $6.3 million and no long-term debt.

"We have sufficient cash to complete the analysis of the results from our cocaine trial and methamphetamine study and to continue our operations through the end of 2010 without additional funding," said Patrick J. McEnany, Catalyst's Chief Executive Officer. "We believe that our financial and human resources are sufficient to pursue a variety of strategies, which we will discuss in detail as they are developed. We are encouraged in that regard by renewed investors' appetite for investing in our industry. While there can be no assurance, we hope, if we obtain positive results from the analysis of our trial data, that we will be able to attract new capital from investors and/or through potential strategic alliances that will allow us to pursue future clinical and non-clinical trials of CPP-109."

"We are currently evaluating the data from our Phase II clinical trial evaluating the use of CPP-109 for the treatment of cocaine addiction and our proof-of-concept study evaluating the use of CPP-109 for the treatment of methamphetamine addiction," continued Mr. McEnany. "We expect to report the results of the cocaine trial and methamphetamine proof-of-concept study by the end of the third quarter of 2009. Based on the results of this analysis, we will evaluate what measures, if any, could be applied to improve the outcome of future studies and will also determine the next steps to be taken regarding the development of CPP-109, including the clinical and non-clinical trials that will be required for us to file an NDA for CPP-109. We will report our future product development plans on
'/>"/>

SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Using catalysts to stamp nanopatterns without ink
2. Experiments reveal unexpected activity of fuel cell catalysts
3. UCT Specialties (Formerly Petrarch) Announces the Release of Their New Product Guides for Silanes, Silicones, Platinum Catalyst and Glass Coatings
4. IDEXX Laboratories Announces First Customer Deliveries of Catalyst Dx(TM) Chemistry Analyzer and SNAPshot Dx(TM) Analyzer
5. Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement
6. Controlling the size of nanoclusters: First step in making new catalysts
7. Catalyst Pharmaceutical Partners Reports Second Quarter 2008 Financial Results
8. NIST and partners identify tiny gold clusters as top-notch catalysts
9. Catalyst Pharmaceutical Partners, Inc. Announces a $4.5 Million Registered Direct Common Stock Offering
10. Catalyst Pharmaceutical Partners to Present at the Rodman & Renshaw 10th Annual Global Investment Conference
11. PointCross Releases Catalyst for Building Business-Ready SharePoint Solutions in 1/10th the Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 19, 2014 Naurex Inc., a biopharmaceutical ... for diseases of the central nervous system, today announced ... executive officer, will present at the 33 rd ... take place at 3:00 p.m. PST on Tuesday, January ... San Francisco, Calif. ...
(Date:12/19/2014)... -- Decision Resources Group finds that the Latin American ... compound annual growth rate through 2023. This is primarily ... increasing adoption of dental implants. Growing aesthetic consciousness in ... demand for dental biomaterials because they can improve the ... Other key findings from Decision Resources Group,s coverage ...
(Date:12/19/2014)... Today, TiFiber, Inc. announced ... and future company headquarters in Fort Smith, Arkansas ... that safely and effectively control dangerous microorganisms. Fort ... historic, strong support for manufacturing, but also due ... technology-based companies such as TiFiber. , In ...
(Date:12/19/2014)... Reports from CDC show approximately 117 ... or more chronic health conditions - including cardiovascular disease, ... of these diseases, but may not eliminate the severe ... implanted nerve stimulation devices today offer relief, they require ... induce side effects. , To eliminate the need ...
Breaking Biology Technology:Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2
... has worked for the last two decades to see if ... in the MIT Technology Review's March/April issue. , ,Richard Weindruch, ... University of Wisconsin-Madison, has been experimenting with low-calorie diets that ... testing on mice is relatively easy, it's too early even ...
... Wis. Third Wave Technologies said on ... significantly increase the value of its intellecual property in the ... Invader line of genetic analysis products with a type of ... company also obtained a Japanese patent for its existing Invader ...
... as a biotechnology leader was greatly enhanced today with ... will be established by UW-Madison. , ,Thats the assessment ... the research institute will be located. Bugher said the ... research into the most basic properties of the flu ...
Cached Biology Technology:Flu institute a booster shot for Wisconsin biotech stature 2Flu institute a booster shot for Wisconsin biotech stature 3
(Date:12/11/2014)... -- That blood pressure plays a role in human health has ... term for high blood pressure – was first described as ... that,s used in measuring blood pressure was invented in 1896. ... hypertension, its triggers and its effects. In fact, recent findings ... best ways to treat it. For example, a ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical ... building for its School of Medicine. Funding for this ... capital campaign that will be publicly launched next summer. ... located in the former 60 series R.J. Reynolds Tobacco ... Quarter. Construction will begin immediately with plans to be ...
(Date:12/5/2014)... , Dec. 4, 2014 Increased emphasis ... investments in new testing and inspection technologies. The ... rise to a range of innovative test solutions. ... of Generation Y, which is generally more inclined ... result, product development strategies of test equipment vendors ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... AWRE ), a leading supplier of broadband technology and biometrics ... 30, 2011.   Revenue for the second quarter of ... million in the same quarter last year. The net loss for ... share. These results compared to a net loss of $148,000, or ...
... Clearbridge Accelerator announced today that it has received an ... in the Silicon Valley. Mr Draper, who is the ... (DFJ), is well known for making early-stage investments in ... Accelerator is a technology incubator that focuses on commercialising ...
... , BLOOMINGTON, Ind. -- A visiting researcher from Sweden in ... has led an international team in culturing, characterizing and formally ... been identified through DNA sequencing from environmental samples. ... Archaeorhizomyces , previously known as Soil Clone Group 1 (SCG1), ...
Cached Biology News:Aware, Inc. Reports Second Quarter 2011 Financial Results 2Aware, Inc. Reports Second Quarter 2011 Financial Results 3Aware, Inc. Reports Second Quarter 2011 Financial Results 4Aware, Inc. Reports Second Quarter 2011 Financial Results 5Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 2Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 3Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 4Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 5Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 6Visiting researcher at IU leads international team in formal identification of new fungi class 2Visiting researcher at IU leads international team in formal identification of new fungi class 3
... of gene expression) technology allows ... profiles generated by SAGE are ... transcripts making it possible to ... Kit is designed to make ...
Sheep Serum US Origin...
... For the ultimate in utility and ... to meet the needs of the researcher. ... interior dimensions or as sheet material that ... enclosures. These isolators are autoclavable and non-cytotoxic ...
2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
Biology Products: